Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Up 102.8% in August

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 17,905 shares, an increase of 102.8% from the July 30th total of 8,827 shares. Based on an average daily volume of 102,216 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the company’s stock are short sold.

Invesco Biotechnology & Genome ETF Trading Down 2.3%

NYSEARCA PBE opened at $96.32 on Friday. Invesco Biotechnology & Genome ETF has a 12 month low of $67.69 and a 12 month high of $98.82. The stock has a 50 day moving average of $92.06 and a 200-day moving average of $84.77. The company has a market cap of $303.41 million, a PE ratio of 20.44 and a beta of 0.70.

Institutional Trading of Invesco Biotechnology & Genome ETF

Large investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its stake in Invesco Biotechnology & Genome ETF by 9,169.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock valued at $28,175,000 after acquiring an additional 339,271 shares during the last quarter. LPL Financial LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 5.0% in the 4th quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock valued at $7,994,000 after purchasing an additional 4,617 shares during the period. United Capital Financial Advisors LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $5,946,000. Royal Bank of Canada lifted its stake in Invesco Biotechnology & Genome ETF by 22.3% in the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after purchasing an additional 13,767 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Invesco Biotechnology & Genome ETF by 2.5% in the 3rd quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock valued at $4,186,000 after purchasing an additional 1,453 shares during the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.